GFM
AQST icon

GF Fund Management’s Aquestive Therapeutics AQST Stock Holding History

GF Fund Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.3K Buy
2,727
+330
+14% +$1.34K ﹤0.01% 551
2025
Q4 		$15.5K Sell
2,397
-206
-8% -$1.28K ﹤0.01% 534
2025
Q3 		$14.6K Buy
2,603
+341
+15% +$1.47K ﹤0.01% 523
2025
Q2 		$7.49K Hold
2,262
– – ﹤0.01% 598
2025
Q1 		$6.56K Buy
2,262
+348
+18% +$1.05K ﹤0.01% 606
2024
Q4 		$6.81K Buy
+1,914
New +$8.83K ﹤0.01% 591

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GF Fund Management's AQST Position: Q1 2026 in Review

GF Fund Management increased its Aquestive Therapeutics (AQST) stake by 14% in Q1 2026, buying an estimated $1.34K and bringing the position to 2,727 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #551.

GF Fund Management first reported a position in AQST in Q4 2024 and has held it in 6 quarters since. The position peaked at $15.5K in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • GF Fund Management held 2,727 shares of Aquestive Therapeutics worth $11.3K as of Q1 2026.
  • GF Fund Management bought 330 Aquestive Therapeutics shares in Q1 2026, an estimated $1.34K.
  • Aquestive Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #551 holding.
  • GF Fund Management first reported a position in Aquestive Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Aquestive Therapeutics position peaked at $15.5K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.